Clinical observations report that patients using BPC-157 experience significant improvements in mobility and pain reduction, with some noting relief lasting six months or longer
May 15, 2025: Analysis Says People Taking Mounjaro Lose More Weight Than On Other GLP-1s A new analysis of post-clinical trial data has shown that people taking Mounjaro lose more weight than when taking most other GLP-1 drugs
Beyond the pipeline, investors should examine whether the company has demonstrated disciplined capital allocation reinvesting cliff-period cash flows into acquisitions or internal development rather than returning all capital to shareholders in a manner that leaves the company underinvested in its post-cliff portfolio
The [Wolverine Peptide Stack]( is a research combination of BPC-157 and TB-500, designed for studying the potential synergistic effects of both compounds on tissue repair and recovery.
The Phase 1 trial in 80 healthy volunteers demonstrated safety and tolerability across four dose levels with no serious adverse events
Myasthenia gravis (77) and encephalitis are more common with anti-PD-1 antibodies, whereas Guillain Barr and meningitis are more common with ipilimumab
